Thus, targeting Brachyury can be a fruitful strategy to attack breast cancer cells that might have lost HER2 expression or dependency during metastasis and progression. Deletion of the nuclear localization sequence of the Brachyury protein led to localization of Brachyury exclusively in the cytoplasm of infected cells. Here, ERBB2 is linked to breast carcinoma.